In this episode we explore the properties of a lesser known cannabinoid & its therapeutic potential.
Do you like what you see?
Read more on:
Follow us on:
The studies cited in this video are:
Rhee, M. H., Vogel, Z., Barg, J., Bayewitch, M., Levy, R., Hanuš, L., Breur, A. & Mechoulam, R. 1997. Cannabinol Derivatives: Binding to Cannabinoid Receptors and Inhibition of Adenylylcyclase. Journal of Medicinal Chemistry, 40, 3228-3233.
Flaubert, B. L. & Kaminsky, N. E. (2000). AP-1 activity is negatively regulated by cannabinol through inhibition of its protein components, c-fos and c-jun. J Leukoc Biol, 67, 259-66.
Herring, A. C., Faubert Kaplan, B. L. & Kaminsky, N. E. (2001). Modulation of CREB and NF-κB signal transduction by cannabinol in activated thymocytes. Cellular Signalling, 13, 241-250.
Turner CE, Elsohly MA, Boeren EG (1980). Constituents of Cannabis sativa L. XVII. A review of the natural constituents. J Nat Prod 43: 169–234.
Qin N, Neeper MP, Liu Y, Hutchinson TL, Lubin ML, Flores CM (2008). TRPV2 is activated by cannabidiol and mediates CGRP release in cultured rat dorsal root ganglion neurons. J Neurosci 28:
Wilkinson JD, Williamson EM (2007). Cannabinoids inhibit human keratinocyte proliferation through a non-CB1/CB2 mechanism and have a potential therapeutic value in the treatment of psoriasis. J Dermatol Sci 45: 87–92.
Scutt A, Williamson EM (2007). Cannabinoids stimulate fibroblastic colony formation by bone marrow cells indirectly via CB2 receptors. Calcif Tissue Int 80: 50–59.
Holland ML, Allen JD, Arnold JC (2008). Interaction of plant cannabinoids with the multidrug transporter ABCC1 (MRP1). Eur J Pharmacol 591: 128–131.